Two Sides of the CGT Coin: Development & The Patient Journey | ATW 2025
Cell and gene therapy (CGT) is about more than just scientific breakthroughs—patient impact is at the heart of every innovation. This session, hosted by Charles River, explores both sides of the CGT coin: development and the patient journey.
💡 Highlights:
⚙️ Part 1: Alan Smith leads a panel discussion on investment, scalable manufacturing, regulatory hurdles, and patient access
🔥 Part 2: Matt Hewitt & Brett Kopelan discuss the rare disease journey, featuring Brett’s advocacy for Epidermolysis Bullosa, a rare skin disorder
Speakers:
🔹 Alan Smith – Executive Director, Operations Excellence, Biomanufacturing, Charles River Laboratories (Chair)
🔹 Jeff Holder – Managing Director, L.E.K. Consulting
🔹 Joe Senesac – CTO, NKILT Therapeutics
🔹 Robert Allen – Managing Partner, Dark Horse Consulting Group
🔹 Phil Vanek – Chief Commercialization Officer, ISCT
🔹 Matthew Hewitt – VP, CTO Manufacturing Business Division, Charles River Laboratories
🔹 Brett Kopelan – Executive Director, debra of America
🎟️ Be part of the next chapter in CGT!
🔹 Pre-register for Advanced Therapies Week 2026 → https://ow.ly/5Ssp50Vaotw
📖 Download the ATW 2025 Show Brochure → https://ow.ly/raF450Vaouz
#ATW26 #CellAndGeneTherapy #PatientJourney #RareDiseases #CGTDevelopment #BiotechInnovation #AdvancedTherapies